CA3266315A1 - Nerve Growth Factor (NGF) for the Treatment of Spasticity - Google Patents
Nerve Growth Factor (NGF) for the Treatment of SpasticityInfo
- Publication number
- CA3266315A1 CA3266315A1 CA3266315A CA3266315A CA3266315A1 CA 3266315 A1 CA3266315 A1 CA 3266315A1 CA 3266315 A CA3266315 A CA 3266315A CA 3266315 A CA3266315 A CA 3266315A CA 3266315 A1 CA3266315 A1 CA 3266315A1
- Authority
- CA
- Canada
- Prior art keywords
- spasticity
- ngf
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22197562.6 | 2022-09-23 | ||
| EP22197562.6A EP4342485A1 (en) | 2022-09-23 | 2022-09-23 | Ngf for the treatment of spasticity |
| PCT/EP2023/076387 WO2024062135A1 (en) | 2022-09-23 | 2023-09-25 | Ngf for the treatment of spasticity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3266315A1 true CA3266315A1 (en) | 2024-03-28 |
Family
ID=83438536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3266315A Pending CA3266315A1 (en) | 2022-09-23 | 2023-09-25 | Nerve Growth Factor (NGF) for the Treatment of Spasticity |
Country Status (10)
| Country | Link |
|---|---|
| EP (3) | EP4342485A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025532676A (cg-RX-API-DMAC10.html) |
| CN (1) | CN120239610A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023345675A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3266315A1 (cg-RX-API-DMAC10.html) |
| DK (1) | DK4590324T3 (cg-RX-API-DMAC10.html) |
| FI (1) | FI4590324T3 (cg-RX-API-DMAC10.html) |
| IL (1) | IL319010A (cg-RX-API-DMAC10.html) |
| PT (1) | PT4590324T (cg-RX-API-DMAC10.html) |
| WO (1) | WO2024062135A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4623927A1 (en) | 2024-03-27 | 2025-10-01 | Dompe' Farmaceutici SpA | Ngf for use in the prevention or treatment of motor impairment caused by neonatal hypoxic-ischemic encephalopathy |
| WO2026022244A1 (en) | 2024-07-23 | 2026-01-29 | Chiesi Farmaceutici S.P.A. | A polypeptide for use in the therapeutic management of acute ischaemic stroke |
| US20260166124A1 (en) * | 2024-12-17 | 2026-06-18 | Dompe` farmaceutici S.P.A. | Intranasal administration of ngf for the prevention or treatment of retinopathies and optic nerve disorders |
| EP4763217A1 (en) * | 2024-12-17 | 2026-06-24 | Dompé farmaceutici SpA | Intranasal administration of ngf for the prevention or treatment of retinopathies and optic nerve disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE257514T1 (de) | 1998-10-09 | 2004-01-15 | Scil Proteins Gmbh | Verfahren zur gewinnung von aktivem beta-ngf |
| CN1112215C (zh) * | 1999-12-28 | 2003-06-25 | 潘晓东 | 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途 |
| ES2545701T3 (es) | 2011-12-19 | 2015-09-15 | Wacker Chemie Ag | Nuevos mutantes de proNGF y usos de los mismos en la producción de beta-NGF |
| CN109071678B (zh) * | 2016-03-18 | 2022-05-20 | 舒泰神（北京）生物制药股份有限公司 | 神经生长因子融合蛋白、制备方法及其用途 |
| IT201600112420A1 (it) * | 2016-11-08 | 2018-05-08 | Univ Cattolica Del Sacro Cuore | Nuova formulazione per via intranasale |
| WO2019207106A1 (en) | 2018-04-27 | 2019-10-31 | Chiesi Farmaceutici Spa | Production of nerve growth factor (ngf) and of muteins thereof |
| AU2020347812B2 (en) * | 2019-09-17 | 2026-05-28 | Chiesi Farmaceutici S.P.A. | Agent for use in treatment or prevention of ophthalmic disorders |
| WO2022105847A1 (en) * | 2020-11-19 | 2022-05-27 | Staidson (Beijing) Biopharmaceuticals Co. , Ltd. | Long-acting nerve growth factor polypeptides and uses thereof |
-
2022
- 2022-09-23 EP EP22197562.6A patent/EP4342485A1/en not_active Withdrawn
-
2023
- 2023-09-25 FI FIEP23777211.6T patent/FI4590324T3/fi active
- 2023-09-25 DK DK23777211.6T patent/DK4590324T3/da active
- 2023-09-25 PT PT237772116T patent/PT4590324T/pt unknown
- 2023-09-25 EP EP23777211.6A patent/EP4590324B1/en active Active
- 2023-09-25 IL IL319010A patent/IL319010A/en unknown
- 2023-09-25 WO PCT/EP2023/076387 patent/WO2024062135A1/en not_active Ceased
- 2023-09-25 AU AU2023345675A patent/AU2023345675A1/en active Pending
- 2023-09-25 CN CN202380067388.4A patent/CN120239610A/zh active Pending
- 2023-09-25 CA CA3266315A patent/CA3266315A1/en active Pending
- 2023-09-25 JP JP2025517344A patent/JP2025532676A/ja active Pending
- 2023-09-25 EP EP26179026.5A patent/EP4772196A3/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4772196A3 (en) | 2026-08-19 |
| DK4590324T3 (en) | 2026-07-20 |
| JP2025532676A (ja) | 2025-10-01 |
| EP4342485A1 (en) | 2024-03-27 |
| EP4590324B1 (en) | 2026-06-24 |
| EP4590324A1 (en) | 2025-07-30 |
| WO2024062135A1 (en) | 2024-03-28 |
| FI4590324T3 (fi) | 2026-07-29 |
| IL319010A (en) | 2025-04-01 |
| PT4590324T (pt) | 2026-07-20 |
| CN120239610A (zh) | 2025-07-01 |
| EP4772196A2 (en) | 2026-07-08 |
| AU2023345675A1 (en) | 2025-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL319010A (en) | NGF for the treatment of spasticity | |
| EP4139280A4 (en) | LINKS TO TREATMENT OF SARS | |
| EP4255401A4 (en) | COMPOUNDS FOR TREATING SARS | |
| AU2022299062B2 (en) | Environmental-friendly process for the treatment of wastewater | |
| EP4245100A4 (en) | SUBSTRATE PROCESSING SYSTEM | |
| CA3263204A1 (en) | TREATMENT FOR MULTIPLE MYELOMA | |
| EP4362963A4 (en) | YEAST FOR THE TREATMENT OF INFLAMMATION | |
| HK40128655A (zh) | 用於治疗抑郁症的方法 | |
| CA3266806A1 (en) | METHODS FOR TREATING DEPRESSION | |
| AU2020904747A0 (en) | System for treatment of substrates | |
| HK40108886A (en) | Aav for the gene therapy of wet-amd | |
| CA3291458A1 (en) | Therapy | |
| CA3271207A1 (en) | Therapy | |
| CA3264674A1 (en) | Treatment of fasciolosis | |
| CA3305498A1 (en) | Methods for the treatment of multiple myeloma | |
| HK40085033A (en) | Tafoxiparin for the treatment of preeclampsia | |
| CA3308179A1 (en) | Londamocitinib for the treatment of asthma | |
| HK40107501A (en) | Gene therapy for treating beta-hemoglobinopathies | |
| HK40081993A (en) | Compounds for the treatment of covid-19 | |
| CA3290995A1 (en) | Gene therapy | |
| CA3286101A1 (en) | Gene therapy | |
| CA3264521A1 (en) | GENE THERAPY | |
| CA3275952A1 (en) | Nootkatone for the treatment of pruritus | |
| AU2023901913A0 (en) | Processes | |
| EP4313077A4 (en) | COMBINATION FOR THE TREATMENT OF THROMBOINTINFECTION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20250224 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20250516 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250516 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250527 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250527 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250527 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250528 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250603 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20250603 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260528 |